MEMORANDUM FOR 959 CSPS  
ATTN: CAPT ANDREW BERGLUND  
FROM: 59 MDW/SGVU  
SUBJECT: Professional Presentation Approval

1. Your paper, entitled *Allergic Bronchopulmonary Mycosis Caused by Cladosporidium* presented at/published to *2017 American Thoracic Society International Conference, Washington D.C., 23 May 2017 (Poster)* in accordance with MDWI 41-108, has been approved and assigned local file #17152.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC  
Director, Clinical Investigations & Research Support

*Warrior Medics — Mission Ready — Patient Focused*
INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SGS O&M); SGS R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants, etc.)
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state “YES” or “NO” in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade, sign and date the form in the author’s signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the “Protocol Title” box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade, title, sign and date the form in the approving authority’s signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDWPA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDWICC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.

11. The Joint Ethics Regulation (JER) DoD 5500.07-R. Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check “NO” in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

   For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

   If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

   If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

   If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

   If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check “YES” in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (202) 767-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc. should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc. should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc. should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

1. TO: CLINICAL RESEARCH
   Capt Andrew Berglund, O-3, Internal Medicine

2. FROM: (Author’s Name, Rank, Grade, Office Symbol)
   Capt Andrew Berglund, O-3, Internal Medicine

3. GME/GHSE STUDENT: [ ] YES [ ] NO

4. PROTOCOL NUMBER: n/a

5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.)
   Allergic Bronchopulmonary Mycosis Caused by Cladosporidium

6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:
   Allergic Bronchopulmonary Mycosis Caused by Cladosporidium

7. FUNDING RECEIVED FOR THIS STUDY? [ ] YES [ ] NO
   FUNDING SOURCE:

8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES? [ ] YES [ ] NO

9. IS THIS MATERIAL CLASSIFIED? [ ] YES [ ] NO

10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? [ ] YES [ ] NO
   NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.

11. MATERIAL IS FOR: [ ] DOMESTIC RELEASE [ ] FOREIGN RELEASE
   CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.
   [ ] 11a. PUBLICATION/JOURNAL (List intended publication/journal.)
   [ ] 11b. PUBLISHED ABSTRACT (List intended journal.)
   [ ] 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)
   [ ] 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)
   [ ] 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)

12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?
   [ ] YES [ ] NO
   ASSIGNED FILE #: __________________ DATE: __________________

13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC
   NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).

   DATE: __________________

14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
    Berglund, Andrew J. email: andrew.j.berglund.mil@mail.mil

15. DUTY PHONE/PAGER NUMBER
    210-513-2908

16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.
   LAST NAME, FIRST NAME AND M.I. GRADE/RANK SQUADRON/GROUP/OFFICE SYMBOL INSTITUTION (If not 59 MDW)
   a. Primary/Corresponding Author
      Berglund, Andrew J. O-3 / Capt 959 CSPS, 59th Medical Wing, Int Med SAUSHEC
   c. Skabelund, Andrew J. O-4 / Maj 59th Medical Wing, Pulmonary Medicine
   d.
   e.

17. IS A 502 ISGUAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? [ ] YES [ ] NO

18. AUTHOR’S PRINTED NAME, RANK, GRADE
    Andrew J. Berglund, Capt, O-3

19. AUTHOR’S SIGNATURE
    BERGLUND ANDREW J. 1395537089

20. DATE
    February 20, 2017

21. APPROVING AUTHORITY’S PRINTED NAME, RANK, TITLE
    David. M. Ferraro, Maj, O-4

22. APPROVING AUTHORITY’S SIGNATURE
    FERRARO DAVID MICHAEL 1267212890

23. DATE
    February 28, 2017

59 MDW FORM 3039, 20160628
PREVIOUS EDITIONS ARE OBSOLETE
Page 2 of 3 Pages
<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 14, 2017</td>
<td>TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>28. DATE REVIEWED</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: NO YES If yes, give date.</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>27. DATE FORWARDED TO 502 ISGU/JAC</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>29. COMMENTS APPROVED DISAPPROVED Case study presentation with appropriate disclaimers. Approved</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>32. DATE REVIEWED</td>
</tr>
<tr>
<td>March 17, 2017</td>
<td>39. DATE REVIEWED</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>43. DATE REVIEWED</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>47. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>31. REVIEWER SIGNATURE</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>35. COMMENTS APPROVED (in compliance with security and policy review directives.)</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>42. REVIEWER SIGNATURE</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>44. DATE REVIEWED</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>37. REVIEWER SIGNATURE</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>45. DATE REVIEWED</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>38. DATE REVIEWED</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>46. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>39. REVIEWER SIGNATURE</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>47. COMMENTS APPROVED DISAPPROVED</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>40. DATE REVIEWED</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</td>
</tr>
<tr>
<td>March 15, 2017</td>
<td>41. COMMENTS APPROVED (in compliance with security and policy review directives.)</td>
</tr>
<tr>
<td>March 20, 2017</td>
<td>49. REVIEWER SIGNATURE</td>
</tr>
</tbody>
</table>
Title: Allergic Bronchopulmonary Mycosis caused by Cladosporium

Authors: Andrew J. Berglund M.D., Amaya George D.O., Andrew Skabelund M.D.

Introduction: Allergic bronchopulmonary mycosis (ABPM) is a hypersensitivity-mediated disease that affects patients all over the world. *Cladosporium* has recently begun to be recognized as one of the many causes of ABPM, however documented reactions in humans are still limited to two case reports only. We describe a case of ABPM caused by *Cladosporium* with classic features on presentation and confirmation with cultures obtained from bronchoalveolar lavage (BAL).

Case Presentation: A 58 year-old female was evaluated in the pulmonary clinic for worsening episodes of cough, chest tightness, and hypoxia that had led to several recent hospital admissions. During each admission, she was given a short course of steroids which improved her symptoms, which returned after stopping the medication. During her prior admission, she underwent bronchoscopy with BAL which demonstrated thick mucus plugs and extensive endobronchial inflammation. Endobronchial brushings and BAL showed inflammatory cells with 6% eosinophils, but all bacterial and AFB cultures were negative. Her exam at this time was notable for clear lung fields. Pertinent labs included: IgE 1040 IU/mL, Aspergillus IgE < 0.35 kU/L, peripheral eosinophilia of 500/μL. Serial chest CT scans showed intermittent ground glass opacities. Spirometry had a positive bronchodilator response. Fungal cultures grew *Cladosporium*. A diagnosis of ABPM secondary to *Cladosporium* was made and the patient was started on a prednisone taper and omalizumab with improvement in symptoms.

Discussion: *Cladosporium* is a ubiquitous mold found in the ground, and is a very rare cause of human illness. Only two cases of *Cladosporium* causing ABPM have been documented in literature to date. Asthma and cystic fibrosis are two of the most important underlying conditions associated with ABPM, but recent literature suggests that up to 70% of cases involve people who are not asthmatics such as this patient. Common laboratory findings include an elevated IgE level and peripheral blood eosinophilia. Chest X-rays can show transient pulmonary infiltrates, while chest CT scans often show central bronchiectasis. Treatment of ABPM focuses on suppressing the immune response with steroid tapers on the order of 3 to 6 months, and avoidance of known exposures to the offending pathogen. Our patient was an avid gardener, and she likely acquired the fungus from her garden soil. The routine use of antifungal therapy has not been studied enough to know if this is beneficial.

Disclaimer:
The views expressed are those of the author(s)/presenter(s) and do not reflect the official view or policy of the Department of Defense or its Components.